{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:18:18Z","timestamp":1792444698502,"version":"4.5.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","funder":[{"DOI":"10.13039\/100016989","name":"Korea University Medicine","doi-asserted-by":"crossref","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100016989","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The global prevalence of macrolide-resistant <jats:italic toggle=\"yes\">Mycoplasma pneumoniae<\/jats:italic> (MRMP) pneumonia infections, particularly in children, is on the rise. It is imperative to assess the clinical efficacies of alternative antibiotics such as tetracyclines to ensure effective treatment, mitigate antibiotic resistance, enhance clinical outcomes, and minimize the spread of resistant strains among MRMP-infected children. The objective of this study was to compare the therapeutic efficacies of macrolides and tetracyclines in treating MRMP pneumonia in children.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We systematically searched the literature to identify comparative studies that examined the clinical outcomes of macrolide and tetracycline antibiotics in children with MRMP pneumonia. We conducted a meta-analysis of the mean duration of fever, hospital stay duration, therapeutic efficacies, and time to defervescence to compare macrolides and tetracyclines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Eleven studies involving 1143 patients compared the clinical efficacies of macrolides and tetracyclines in children with MRMP pneumonia. The studies were conducted in China, Japan, and Korea, and the outcomes of febrile days, hospital stay duration, therapeutic efficacy, and time to defervescence were analyzed. The macrolides studied were azithromycin and clarithromycin, whereas the tetracyclines included minocycline and doxycycline. The pooled estimate of 5 studies showed that the mean duration of febrile days and hospital stay was longer in the macrolides group than tetracycline group [weighted mean difference = 1.64 days, 95% confidence interval (CI): 0.68\u20132.59, weighted mean difference = 1.22 days, 95% CI: 0.82\u20131.62, respectively]. The therapeutic efficacy was significantly lower in the macrolide group than in the tetracycline group (odds ratio: 0.33, 95% CI: 0.20\u20130.57).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>The clinical efficacy of tetracycline treatment was superior to that of macrolide treatment in children with MRMP pneumonia. However, further research is required to validate these findings and inform evidence-based clinical practice guidelines.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004568","type":"journal-article","created":{"date-parts":[[2024,10,9]],"date-time":"2024-10-09T19:04:51Z","timestamp":1728500691000},"page":"200-206","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["Treatment of Macrolide-resistant Mycoplasma pneumoniae Pneumonia in Children: A Meta-analysis of Macrolides Versus Tetracyclines"],"prefix":"10.1097","volume":"44","author":[{"given":"Erdenetuya","family":"Bolormaa","sequence":"first","affiliation":[{"name":"Department of Preventive Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Young","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Korea University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2733-0715","authenticated-orcid":false,"given":"Young June","family":"Choe","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Korea University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cho Ryok","family":"Kang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Korea University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Ah","family":"Choe","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftherios","family":"Mylonakis","sequence":"additional","affiliation":[{"name":"Department of Medicine, Houston Methodist Hospital, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,2]]},"reference":[{"key":"R1-20250214","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/cid\/ciy419","article-title":"Mycoplasma pneumoniae among children hospitalized with community-acquired pneumonia.","volume":"68","author":"Kutty","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R2-20250214","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1128\/CMR.17.4.697-728.2004","article-title":"Mycoplasma pneumoniae and its role as a human pathogen.","volume":"17","author":"Waites","year":"2004","journal-title":"Clin Microbiol Rev"},{"key":"R3-20250214","doi-asserted-by":"crossref","first-page":"e2220949","DOI":"10.1001\/jamanetworkopen.2022.20949","article-title":"Global trends in the proportion of macrolide-resistant Mycoplasma pneumoniae infections: a systematic review and meta-analysis.","volume":"5","author":"Kim","year":"2022","journal-title":"JAMA Netw Open"},{"key":"R4-20250214","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1128\/AAC.01806-13","article-title":"More complications occur in macrolide-resistant than in macrolide-sensitive Mycoplasma pneumoniae pneumonia.","volume":"58","author":"Zhou","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"R5-20250214","article-title":"The Japanese Society of Mycoplasmology: guiding principles for treating Mycoplasma pneumoniae pneumonia.","author":"Kohno"},{"key":"R6-20250214","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jmii.2020.10.002","article-title":"Rational stepwise approach for Mycoplasma pneumoniae pneumonia in children.","volume":"54","author":"Tsai","year":"2021","journal-title":"J Microbiol Immunol Infect"},{"key":"R7-20250214","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1186\/s12879-021-06508-7","article-title":"Efficacy of tetracyclines and fluoroquinolones for the treatment of macrolide-refractory Mycoplasma pneumoniae pneumonia in children: a systematic review and meta-analysis.","volume":"21","author":"Ahn","year":"2021","journal-title":"BMC Infect Dis"},{"key":"R8-20250214","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1542\/peds.47.3.567","article-title":"Tetracyclines and permanent teeth: the relation between dose and tooth color.","volume":"47","author":"Grossman","year":"1971","journal-title":"Pediatrics"},{"key":"R9-20250214","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3389\/fmicb.2016.00974","article-title":"Mycoplasma pneumoniae: current knowledge on macrolide resistance and treatment.","volume":"7","author":"Pereyre","year":"2016","journal-title":"Front Microbiol"},{"key":"R10-20250214","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1128\/AAC.00048-13","article-title":"Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients.","volume":"57","author":"Kawai","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"R11-20250214","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"R12-20250214","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement.","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"R13-20250214","doi-asserted-by":"crossref","first-page":"e268","DOI":"10.3346\/jkms.2018.33.e268","article-title":"Therapeutic efficacy and safety of prolonged macrolide, corticosteroid, doxycycline, and levofloxacin against macrolide-unresponsive Mycoplasma pneumoniae pneumonia in children.","volume":"33","author":"Ha","year":"2018","journal-title":"J Korean Med Sci"},{"key":"R14-20250214","doi-asserted-by":"crossref","first-page":"e0173635","DOI":"10.1371\/journal.pone.0173635","article-title":"Therapeutic efficacy of azithromycin, clarithromycin, minocycline and tosufloxacin against macrolide-resistant and macrolide-sensitive Mycoplasma pneumoniae pneumonia in pediatric patients.","volume":"12","author":"Ishiguro","year":"2017","journal-title":"PLoS One"},{"key":"R15-20250214","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3390\/antibiotics10020192","article-title":"Clinical efficacy of doxycycline for treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children.","volume":"10","author":"Lee","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"R16-20250214","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/crj.13549","article-title":"Assessment of variables associated with prolonged admission duration in children with Mycoplasma pneumoniae pneumonia.","volume":"16","author":"Sung","year":"2022","journal-title":"Clin Respir J"},{"key":"R17-20250214","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1093\/cid\/cis784","article-title":"Rapid effectiveness of minocycline or doxycycline against macrolide-resistant Mycoplasma pneumoniae infection in a 2011 outbreak among Japanese children.","volume":"55","author":"Okada","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R18-20250214","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1440-1843.2011.02102.x","article-title":"Clinical efficacy of macrolide antibiotics against genetically determined macrolide-resistant Mycoplasma pneumoniae pneumonia in paediatric patients.","volume":"17","author":"Kawai","year":"2012","journal-title":"Respirology"},{"key":"R19-20250214","first-page":"17","article-title":"Minocycline in children with macrolide-resistant Mycoplasma pneumoniae pneumonia.","volume":"22","author":"Han","year":"2016","journal-title":"J Pediatr Pharm"},{"key":"R20-20250214","first-page":"102","article-title":"Analyze on the influence of minocycline combined with azithromycin on serum CRP, D-Dimer and lung function in the children with refractory mycoplasma pneumonia.","volume":"37","author":"Li","year":"2017","journal-title":"Chin J Biochem Pharm"},{"key":"R21-20250214","first-page":"659","article-title":"Therapeutic effects of minocycline on MRMP in children over 8 years.","volume":"38","author":"Zhang","year":"2016","journal-title":"Hebei Med J"},{"key":"R22-20250214","first-page":"121","article-title":"Evaluation of the curative effects of doxycycline in the treatment of pediatric macrolide-resistant mycoplasma pneumonia.","volume":"54","author":"Ye","year":"2016","journal-title":"China Modern Doctor"},{"key":"R23-20250214","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.3201\/eid1908.121455","article-title":"Macrolide resistance of Mycoplasma pneumoniae, South Korea, 2000\u20132011.","volume":"19","author":"Hong","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"R24-20250214","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1128\/AAC.48.2.460-465.2004","article-title":"In vitro selection and characterization of resistance to macrolides and related antibiotics in Mycoplasma pneumoniae.","volume":"48","author":"Pereyre","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R25-20250214","doi-asserted-by":"crossref","first-page":"3001","DOI":"10.1007\/s00431-024-05519-1","article-title":"Challenges in the treatment of pediatric Mycoplasma pneumoniae pneumonia.","volume":"183","author":"Ding","year":"2024","journal-title":"Eur J Pediatr"},{"key":"R26-20250214","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0950268824000323","article-title":"Macrolide-resistance of Mycoplasma pneumoniae in several regions of China from 2013 to 2019.","volume":"152","author":"Jiang","year":"2024","journal-title":"Epidemiol Infect"},{"key":"R27-20250214","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.3390\/antibiotics11091233","article-title":"Macrolide versus non-macrolide in combination with steroids for the treatment of lobar or segmental Mycoplasma pneumoniae pneumonia unresponsive to initial macrolide monotherapy.","volume":"11","author":"Bae","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"R28-20250214","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/j.jfma.2022.05.001","article-title":"Children with Mycoplasma pneumoniae infection in Taiwan: changes in molecular characteristics and clinical outcomes.","volume":"121","author":"Charlotte Hsiung","year":"2022","journal-title":"J Formos Med Assoc"},{"key":"R29-20250214","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1442-200X.2010.03316.x","article-title":"Japanese guidelines for the management of respiratory infectious diseases in children 2007 with focus on pneumonia.","volume":"53","author":"Uehara","year":"2011","journal-title":"Pediatr Int"},{"key":"R30-20250214","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1440-1843.2012.02227.x","article-title":"Evaluation of the Japanese Respiratory Society Guidelines for the identification of Mycoplasma pneumoniae pneumonia.","volume":"17","author":"Yin","year":"2012","journal-title":"Respirology"},{"key":"R31-20250214","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1177\/1060028019863796","article-title":"Doxycycline and tooth discoloration in children: changing of recommendations based on evidence of safety.","volume":"53","author":"Stultz","year":"2019","journal-title":"Ann Pharmacother"},{"key":"R32-20250214","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4066\/AMJ.2015.2335","article-title":"Still leaving stains on teeth-the legacy of minocycline?","volume":"8","author":"Raymond","year":"2015","journal-title":"Australas Med J"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004568","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T17:01:26Z","timestamp":1739552486000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,2]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004568","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,2]]}}}